Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Translational Oncology Research International
With
OBJECTIVES: Primary * Compare objective tumor response in patients stage IIIB or IV non-small cell lung cancer treated with erlotinib hydrochloride with vs without fulvestrant. Secondary * Correlate response rate with ER and EGF receptor expression in patients treated with these regimens. * Correlate measurement of ER-α, ER-β, EGF/HER-1 receptor and HER-2/neu receptor with clinical response in patients treated with these regimens. * Correlate erlotinib hydrochloride resistance with ER and HER receptor expression in patients treated with these regimens. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to performance status, gender, and participating center. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days. * Arm II: Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter. In both arms, treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for 30 days and then every 2 months until disease progression. PROJECTED ACCRUAL: A total of 102 patients (34 in arm I and 68 in arm II) will be accrued for this study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
